The University of Chicago was awarded a $5,656,759.38 Firm Fixed Price contract by the National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccines for influenza using an immuno-modulator adjuvant and multi-platform approach. This contract, which does not have a set-aside designation, is part of a larger $146.3 million Indefinite Delivery Vehicle (IDV) that the university holds with NIAID for pre-clinical models of infectious diseases. The IDV supports the evaluation and development of animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. As a renowned private research university, the University of Chicago leverages its expertise and resources to conduct cutting-edge research across disciplines, including medicine and infectious disease, in support of federal agencies and national priorities.
Generated 9/12/24, 9:53 AM